Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Sprowl

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|October 23, 2012
Drug trafficking: recent advances in therapeutics and diseaseJ A Sprowl, A Sparreboom
The Pharmacogenomics Journal|February 4, 2010
The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistanceK Reed, S L Hembruff, J A Sprowl, et al.
Clinical Pharmacology and Therapeutics|April 27, 2012
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacyJ A Sprowl, V Gregorc, C Lazzari, et al.
Clinical Pharmacology and Therapeutics|July 19, 2013
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearanceJ A Sprowl, L van Doorn, S Hu, et al.
Clinical and Translational Science|July 10, 2017
Identification of OAT1/OAT3 as Contributors to Cisplatin ToxicityS Hu, A F Leblanc, A A Gibson, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|October 23, 2012
Drug trafficking: recent advances in therapeutics and diseaseJ A Sprowl, A Sparreboom
The Pharmacogenomics Journal|February 4, 2010
The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistanceK Reed, S L Hembruff, J A Sprowl, et al.
Clinical Pharmacology and Therapeutics|April 27, 2012
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacyJ A Sprowl, V Gregorc, C Lazzari, et al.
Clinical Pharmacology and Therapeutics|July 19, 2013
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearanceJ A Sprowl, L van Doorn, S Hu, et al.
Clinical and Translational Science|July 10, 2017
Identification of OAT1/OAT3 as Contributors to Cisplatin ToxicityS Hu, A F Leblanc, A A Gibson, et al.
Pageof 1